Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; maize starch; copovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: copovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; croscarmellose sodium; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Canada - English - Health Canada

pharmascience inc - escitalopram (escitalopram oxalate) - tablet - 10mg - escitalopram (escitalopram oxalate) 10mg - selective-serotonin reuptake inhibitors

Canada - English - Health Canada

pharmascience inc - escitalopram (escitalopram oxalate) - tablet - 20mg - escitalopram (escitalopram oxalate) 20mg - selective-serotonin reuptake inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified water; macrogol 400; microcrystalline cellulose; purified talc; croscarmellose sodium; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; maize starch; pregelatinised maize starch - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 49.98 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; microcrystalline cellulose; purified talc; pregelatinised maize starch; macrogol 400; lactose monohydrate; purified water; maize starch; titanium dioxide - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.47 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; magnesium stearate; purified talc; hypromellose; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.74 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; croscarmellose sodium; macrogol 400; hypromellose; titanium dioxide; microcrystalline cellulose; magnesium stearate - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

United States - English - NLM (National Library of Medicine)

hikma pharmaceutical - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg - escitalopram tablets, usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)].   a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets, usp are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)].   generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persist

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 20 mg - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy